ESTRO Brachytherapy for Prostate Cancer 2018

The controversy !

Point: the relationship between postimplant dose

metrics and biochemical no evidence of disease

following low dose rate prostate brachytherapy: is

there an elephant in the room?

Morris WJ , Halperin R , Spadinger I

Counterpoint: there is a dose-response

relationship in the low-dose rate brachytherapy

management of prostate cancer.

Stock RG .

Brachytherapy. 2010 Oct-Dec;9(4):289-92; discussion 297-8.